Japanese guidance for use of biologics for psoriasis (the 2019 version)

• Published in: Journal of dermatology Vol. 47; no. 3; pp. 201 - 222
• Main Authors: Saeki, Hidehisa, Terui, Tadashi, Morita, Akimichi, Sano, Shigetoshi, Imafuku, Shinichi, Asahina, Akihiko, Komine, Mayumi, Etoh, Takafumi, Igarashi, Atsuyuki, Torii, Hideshi, Abe, Masatoshi, Nakagawa, Hidemi, Watanabe, Akira, Yotsuyanagi, Hiroshi, Ohtsuki, Mamitaro
• Format: Journal Article
• Language: English
• Published: England Wiley Subscription Services, Inc 01.03.2020
• Subjects: Adalimumab - therapeutic use; Antibodies, Monoclonal - therapeutic use; Antibodies, Monoclonal, Humanized - therapeutic use; Arthritis; Biological products; Biological Products - therapeutic use; biologics; Contraindications, Drug; Dermatologic Agents - administration & dosage; Dermatologic Agents - adverse effects; Dermatologic Agents - therapeutic use; Drug Substitution - standards; Drug Therapy, Combination; Humans; Immunoglobulins; Infliximab; Infliximab - therapeutic use; interleukin‐17; interleukin‐23; Japan; Monoclonal antibodies; Patient Care Planning; Patient Selection; Patients; Psoriasis; Psoriasis - drug therapy; Tumor necrosis factor-α; Ustekinumab - therapeutic use; Japan; interleukin-17; biologics; psoriasis; tumor necrosis factor-α; interleukin-23

As the first biologics for psoriasis in Japan, infliximab and adalimumab, anti‐tumor necrosis factor‐α antibodies, became available in the field of dermatology in 2010, followed by ustekinumab, an anti‐interleukin (IL)‐12/IL‐23p40 antibody, which was launched in Japan in 2011. Since 2015, three IL‐1...